Immuron Limited Launches PROIBS® for IBS Treatment

Immuron Limited announced the official launch of PROIBS®, a treatment for Irritable Bowel Syndrome (IBS), into the Australian market. The product, which has already received pharmacy orders, is designed to address symptoms such as abdominal pain, bloating, and unsettled bowel movements. PROIBS® contains AVH200®, derived from Aloe barbadensis, which supports the intestinal mucosal barrier. The launch is timed for the peak festive season when IBS symptoms are most prevalent. Immuron plans to focus on online and selected pharmacies, supported by a digital marketing and social media campaign. The IBS treatment market in Australia is part of a broader market generating around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.